Obbligazioni societarie HIGH YIELD e oltre, verso frontiere inesplorate - Vol. 2

Gentile Signor

facendo riferimento all?offerta sul titolo COMMUNITY HEALTH SYS 8% 12/19 (isin US12543DAL47) e COMMUNITY HEALTH SYS 6,875% 14/22 (isin US12543DAV29), La informiamo che successivamente alle informazioni pervenute l?operazione presenta delle restrizione tali per cui non ci risulta possibile aderire come da Sua indicazione.
L?operazione e riservata ai soli investitori professionali, di seguito la comunicazione ricevuta:

" Notice to Prospective Investors in the EEA: The New Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (?EEA?). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, ?MiFID II?); or (ii) a customer within the meaning of Directive 2002/92/EC (as amended, the ?Insurance Mediation Directive?), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Directive 2003/71/EC (as amended, the ?Prospectus Directive?). Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the ?PRIIPs Regulation?) for offering or selling the New Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the New Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPS Regulation. This Offering Memorandum has been prepared on the basis that any offer of the new Notes in any member state of the EEA will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of notes. This Offering Memorandum is not a prospectus for the purposes of the Prospectus Directive."

vorrà dire che mi terrò le vecchie
 
Gentile Signor

facendo riferimento all?offerta sul titolo COMMUNITY HEALTH SYS 8% 12/19 (isin US12543DAL47) e COMMUNITY HEALTH SYS 6,875% 14/22 (isin US12543DAV29), La informiamo che successivamente alle informazioni pervenute l?operazione presenta delle restrizione tali per cui non ci risulta possibile aderire come da Sua indicazione.
L?operazione e riservata ai soli investitori professionali, di seguito la comunicazione ricevuta:

vorrà dire che mi terrò le vecchie

Chi è che ti fa la comunicazione?
 
Rating Action:
Moody's upgrades JBS' corporate family rating to B1, stable outlook

18 May 2018
New York, May 18, 2018 -- Moody's Investors Service upgraded JBS S.A. (JBS) 's corporate family rating to B1 from B3. At the same time, the senior unsecured ratings of its wholly-owned subsidiary JBS USA Lux S.A. ("JBS USA") were upgraded to B1 from B2 and its senior secured ratings to Ba3 from B1. The outlook for all ratings is stable.



The debt instruments being upgraded include JBS USA's $2.8 billion senior secured term loan due 2022 that will be expanded through a $450 million add-on that was launched on May 16th.



The positive action follows the announcement of the Normalization Agreement made by the company to maintain access to certain credit lines for three years, until 2021, which reduces liquidity risk, as well as the continued supportive operational results.
 
Rating Action:
Moody's downgrades Mattel's senior unsecured guaranteed bonds to B1; affirms other ratings; outlook stable

21 May 2018
New York, May 21, 2018 -- Moody's Investors Service, ("Moody's") downgraded Mattel, Inc.'s ("Mattel") senior unsecured guaranteed notes due 2025 to B1 following the announcement that the company will add-on an additional $500 million to the issue to prepay $500 million in unguaranteed notes due May 2019. The company's Corporate Family Rating and Probability of Default Rating of B1 and B1-PD, its unguaranteed unsecured notes at B3 and its speculative grade liquidity rating of SGL-2 were all affirmed. The rating outlook is stable.
 
Questi due titoli Altice Luxembourg hanno poca differenza di prezzo, nonostante la cedola e la scadenza:
XS1117300241 15.02.25 cedola 6,25%
XS1061642317 15.05.22 cedola 7,25%
C'è una ragione (secured)?
 
Questi due titoli Altice Luxembourg hanno poca differenza di prezzo, nonostante la cedola e la scadenza:
XS1117300241 15.02.25 cedola 6,25%
XS1061642317 15.05.22 cedola 7,25%
C'è una ragione (secured)?
non sò la risposta ma per complicarti le cose ci sarebbe anche questa che quota strano su Finra ed è sparita dalle borse tedesche 7,625% 15/2/25
USL0179ZAC88
 

Users who are viewing this thread

Back
Alto